- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT05068011
Differentialmål multiplexerad ryggmärgsstimulering (DETECT)
Differentiellt mål multiplexerad ryggmärgsstimulering: en multicenterkohortstudie
Evaluation of the effectiveness of differential target multiplexed spinal cord stimulation for treatment of chronic back and leg pain. Additionally, a subgroup analysis will be performed to evaluate potential differences between paddle/surgical leads versus percutaneous leads.
Studieöversikt
Status
Intervention / Behandling
Studietyp
Inskrivning (Beräknad)
Kontakter och platser
Studieorter
-
-
-
Antwerp, Belgien
- ZNA
-
Bruges, Belgien
- AZ Sint-Jan Brugge-Oostende
-
Bruges, Belgien
- AZ Sint-Lucas Brugge
-
Hasselt, Belgien
- Jessa Ziekenhuis
-
Kortrijk, Belgien
- AZ Groeninge
-
Leuven, Belgien
- UZ Leuven
-
Lier, Belgien
- Heilig Hart Ziekenhuis Lier
-
Liège, Belgien
- Centre Hospitalier Régional (CHR) de la Citadelle
-
Mechelen, Belgien
- AZ Sint-Maarten
-
Roeselare, Belgien
- AZ Delta
-
Sint-Niklaas, Belgien
- Vitaz
-
Turnhout, Belgien
- AZ Turnhout
-
Wilrijk, Belgien
- GZA
-
-
Brussels Capital
-
Jette, Brussels Capital, Belgien, 1090
- Universitair Ziekenhuis Brussel
-
-
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
Tar emot friska volontärer
Kön som är behöriga för studier
Testmetod
Studera befolkning
Patients with chronic back and leg pain due to Failed Back Surgery Syndrome (FBSS)/Persistent Spinal Pain Syndrome type 2 (PSPS-T2), who will receive treatment with differential target multiplexed (DTM) SCS.
Beskrivning
Inclusion Criteria:
- Patients with severe chronic pain (> 5 on numeric rating scale, NRS) for at least 6 months due to FBSS (PSPS T2) and suitable for treatment with DTM SCS according to the treating physician
- Age > 18 years
- Patient has been informed of the study procedures and has given written informed consent
- Patient willing to comply with study protocol including attending the study visits
Exclusion Criteria:
- Expected inability of the patient to receive or properly operate the spinal cord stimulation system
- History of coagulation disorder, lupus erythematosus, diabetic neuropathy, rheumatoid arthritis, or morbus Bechterew
- Active malignancy
- Addiction to drugs, alcohol (>5 units per day) and/or medication
- Evidence of an active disruptive psychiatric disorder or other known condition that may impact perception of pain, compliance to the intervention, and/or ability to evaluate treatment outcome as determined by investigator
- Immune deficiency (e.g. HIV positive, immunosuppressive treatment)
- Life expectancy < 1 year
- Local infection or any other skin disorder at site of incision
- Pregnancy
- Other implanted active medical device
Studieplan
Hur är studien utformad?
Designdetaljer
- Observationsmodeller: COHORT
- Tidsperspektiv: PROSPECTIVE
Kohorter och interventioner
Grupp / Kohort |
Intervention / Behandling |
|---|---|
|
Spinal cord stimulation
Patients will receive differential target multiplexed spinal cord stimulation |
differential target multiplexed stimulation |
Vad mäter studien?
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Overall pain intensity with Visual Analogue Scale (VAS)
Tidsram: The change between the baseline screening and the evaluation 1 month after DTM stimulation, 6 months and 12 months
|
Overall pain, defined as a combination of back and leg pain, but not pain from other body parts, measured with the VAS (100mm) |
The change between the baseline screening and the evaluation 1 month after DTM stimulation, 6 months and 12 months
|
Sekundära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Intensitet av ryggsmärtor med Visual Analogue Scale (VAS)
Tidsram: Förändringen mellan baslinjescreeningen och utvärderingen 1 månad efter DTM-stimulering, 6 månader och 12 månader
|
Förändringen mellan baslinjescreeningen och utvärderingen 1 månad efter DTM-stimulering, 6 månader och 12 månader
|
|
|
Bensmärta intensitet med Visual Analogue Scale (VAS)
Tidsram: Förändringen mellan baslinjescreeningen och utvärderingen 1 månad efter DTM-stimulering, 6 månader och 12 månader
|
Förändringen mellan baslinjescreeningen och utvärderingen 1 månad efter DTM-stimulering, 6 månader och 12 månader
|
|
|
Klinisk holistisk responderstatus
Tidsram: Förändringen mellan baslinjescreeningen och utvärderingen 1 månad efter DTM-stimulering, 6 månader och 12 månader
|
Förändringen mellan baslinjescreeningen och utvärderingen 1 månad efter DTM-stimulering, 6 månader och 12 månader
|
|
|
Andel framgångsrika DTM-försök.
Tidsram: Utvärderad efter slutlig SCS-implantation
|
Utvärderad efter slutlig SCS-implantation
|
|
|
Batteriförbrukning
Tidsram: Registrering vid 1 månad, 6 månader och 12 månader av DTM SCS
|
Registrering vid 1 månad, 6 månader och 12 månader av DTM SCS
|
|
|
Förekomst av tekniska problem med avseende på DTM SCS-programmering
Tidsram: Under hela studietiden
|
Under hela studietiden
|
|
|
DTM SCS-stimuleringsparametrar
Tidsram: Registrering vid 1 månad, 6 månader och 12 månader av DTM SCS
|
Registrering vid 1 månad, 6 månader och 12 månader av DTM SCS
|
|
|
Pain medication use
Tidsram: The change between the baseline screening and the evaluation 1 month after DTM stimulation, 6 months and 12 months
|
Open question regarding the dosage, frequency and type of pain medication |
The change between the baseline screening and the evaluation 1 month after DTM stimulation, 6 months and 12 months
|
|
Functional disability
Tidsram: The change between the baseline screening and the evaluation 1 month after DTM stimulation, 6 months and 12 months
|
The functional disabilities will be assessed with the Oswestry Disability Index (ODI) |
The change between the baseline screening and the evaluation 1 month after DTM stimulation, 6 months and 12 months
|
|
Health related quality of life
Tidsram: The change between the baseline screening and the evaluation 1 month after DTM stimulation, 6 months and 12 months
|
Health related quality of life, evaluated with the EuroQol with five dimensions and 5 levels |
The change between the baseline screening and the evaluation 1 month after DTM stimulation, 6 months and 12 months
|
|
Patient global impression of change
Tidsram: Evaluated at 1 month, 6 months and 12 months of DTM SCS.
|
Patients will be asked to quantify the impression of change after treatment using the Patient Global Impression of Change scale (PGIC). |
Evaluated at 1 month, 6 months and 12 months of DTM SCS.
|
|
Patients' individual competencies for self-management
Tidsram: The change between the baseline screening and the evaluation 1 month after DTM stimulation, 6 months and 12 months
|
Patient activation measure-13 (PAM) is a 13-item instrument which assesses self-reported behaviour, knowledge, and confidence for self-management of one's health. |
The change between the baseline screening and the evaluation 1 month after DTM stimulation, 6 months and 12 months
|
|
Work status
Tidsram: The change between the baseline screening and the evaluation 1 month after DTM stimulation, 6 months and 12 months
|
Work status is evaluated with a self-designed questionnaire |
The change between the baseline screening and the evaluation 1 month after DTM stimulation, 6 months and 12 months
|
|
Pain catastrophizing
Tidsram: The change between the baseline screening and the evaluation 1 month after DTM stimulation, 6 months and 12 months
|
The Pain Catastrophizing Scale (PCS) will be used to measure the level of pain catastrophizing |
The change between the baseline screening and the evaluation 1 month after DTM stimulation, 6 months and 12 months
|
|
Symptoms of central sensitisation.
Tidsram: The change between the baseline screening and the evaluation 1 month after DTM stimulation, 6 months and 12 months
|
The Central Sensitization Inventory is used to measure symptoms of central sensitisation |
The change between the baseline screening and the evaluation 1 month after DTM stimulation, 6 months and 12 months
|
|
Anxiety and Depression.
Tidsram: The change between the baseline screening and the evaluation 1 month after DTM stimulation, 6 months and 12 months
|
The hospital Anxiety and Depression Scale (HADS) will measure symptoms of anxiety and depression |
The change between the baseline screening and the evaluation 1 month after DTM stimulation, 6 months and 12 months
|
|
Healthcare utilisation.
Tidsram: The change between implantation and evaluation at 1 month, 6 months and 12 months of DTM SCS
|
Postoperative healthcare expenditure will be investigated by self-reporting methods. |
The change between implantation and evaluation at 1 month, 6 months and 12 months of DTM SCS
|
|
Time spent in body postures
Tidsram: The data will be extracted from SCS implantation up to 1 month of SCS, from 1 month of SCS up to 6 months and from 6 months up to 12 months
|
Based on the AdaptiveStim technology, the time spent in body postures can be recorded. |
The data will be extracted from SCS implantation up to 1 month of SCS, from 1 month of SCS up to 6 months and from 6 months up to 12 months
|
|
(Serious) adverse events
Tidsram: Throughout study period
|
Systematically recording all adverse events |
Throughout study period
|
|
Patient expectations concerning SCS
Tidsram: Evaluated at baseline visit
|
Self-constructed open question to evaluate patient expectations about SCS |
Evaluated at baseline visit
|
Samarbetspartners och utredare
Sponsor
Publikationer och användbara länkar
Studieavstämningsdatum
Studera stora datum
Studiestart (Faktisk)
Primärt slutförande (Beräknad)
Avslutad studie (Beräknad)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Faktisk)
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Ytterligare relevanta MeSH-villkor
Andra studie-ID-nummer
- DETECT
Läkemedels- och apparatinformation, studiedokument
Studerar en amerikansk FDA-reglerad läkemedelsprodukt
Studerar en amerikansk FDA-reglerad produktprodukt
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .